These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25239004)

  • 1. Safety and quality outcomes in peritoneal surface malignancy patients: developing a national center for excellence in Colombia.
    Arias F; Herrera-Almario G; Pozo ME; Londoño-Schimmer E; Otero JM; Cardona A; Cortes N; Mora M
    Ann Surg Oncol; 2015 May; 22(5):1733-8. PubMed ID: 25239004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
    Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
    J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.
    Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U
    Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
    Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
    Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J
    Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center.
    Graziosi L; Marino E; De Angelis V; Rebonato A; Donini A
    World J Surg Oncol; 2016 Mar; 14():97. PubMed ID: 27036213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study.
    Madsen AH; Ladekarl M; Villadsen GE; Grønbæk H; Sørensen MM; Stribolt K; Verwaal VJ; Iversen LH
    Ann Surg Oncol; 2018 Feb; 25(2):422-430. PubMed ID: 29214450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U
    Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
    Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J
    Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O;
    Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Port-site metastases is an independent prognostic factor in patients with peritoneal carcinomatosis.
    Nunez MF; Sardi A; Jimenez W; Nieroda C; Sittig M; MacDonald R; Aydin N; Milovanov V; Gushchin V
    Ann Surg Oncol; 2015 Apr; 22(4):1267-73. PubMed ID: 25319578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.